Homozygous Familial Hypercholesterolemia Epidemiology Market - Global Outlook and Forecast 2021-2027

March 2021 | 91 pages | ID: H64E8FD69FAAEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Homozygous Familial Hypercholesterolemia Epidemiology in Global, including the following market information:

Global Homozygous Familial Hypercholesterolemia Epidemiology Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Homozygous Familial Hypercholesterolemia Epidemiology market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Homozygous Familial Hypercholesterolemia Epidemiology companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Homozygous Familial Hypercholesterolemia Epidemiology Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Homozygous Familial Hypercholesterolemia Epidemiology Market Segment Percentages, By Type, 2020 (%)

• Statins
• MTP inhibitors (Lomitapide)
• PCSK9 inhibitors
• Other

China Homozygous Familial Hypercholesterolemia Epidemiology Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Homozygous Familial Hypercholesterolemia Epidemiology Market Segment Percentages, By Application, 2020 (%)

• Hospital
• Research Institute
• Commercial
• Other

Global Homozygous Familial Hypercholesterolemia Epidemiology Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Homozygous Familial Hypercholesterolemia Epidemiology Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Homozygous Familial Hypercholesterolemia Epidemiology Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Homozygous Familial Hypercholesterolemia Epidemiology Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Regeneron Pharmaceuticals
• Novartis
• LIB Therapeutics
• NeuroBo Pharmaceuticals
• Arrowhead Pharmaceuticals
• Amgen
• Aegerion Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA EPIDEMIOLOGY OVERALL MARKET SIZE

2.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size: 2021 VS 2027
2.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Homozygous Familial Hypercholesterolemia Epidemiology Players in Global Market
3.2 Top Global Homozygous Familial Hypercholesterolemia Epidemiology Companies Ranked by Revenue
3.3 Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue by Companies
3.4 Top 3 and Top 5 Homozygous Familial Hypercholesterolemia Epidemiology Companies in Global Market, by Revenue in 2020
3.5 Global Companies Homozygous Familial Hypercholesterolemia Epidemiology Product Type
3.6 Tier 1, Tier 2 and Tier 3 Homozygous Familial Hypercholesterolemia Epidemiology Players in Global Market
  3.6.1 List of Global Tier 1 Homozygous Familial Hypercholesterolemia Epidemiology Companies
  3.6.2 List of Global Tier 2 and Tier 3 Homozygous Familial Hypercholesterolemia Epidemiology Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Markets, 2021 & 2027
  4.1.2 Statins
  4.1.3 MTP inhibitors (Lomitapide)
  4.1.4 PCSK9 inhibitors
  4.1.5 Other
4.2 By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue & Forecasts
  4.2.1 By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2021
  4.2.2 By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2022-2027
  4.2.3 By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2021 & 2027
  5.1.2 Hospital
  5.1.3 Research Institute
  5.1.4 Commercial
  5.1.5 Other
5.2 By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue & Forecasts
  5.2.1 By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2021
  5.2.2 By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2022-2027
  5.2.3 By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2021 & 2027
6.2 By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue & Forecasts
  6.2.1 By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2021
  6.2.2 By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2022-2027
  6.2.3 By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027
  6.3.2 US Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.3.3 Canada Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.3.4 Mexico Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027
  6.4.2 Germany Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.3 France Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.4 U.K. Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.5 Italy Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.6 Russia Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.7 Nordic Countries Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.4.8 Benelux Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027
  6.5.2 China Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.5.3 Japan Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.5.4 South Korea Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.5.5 Southeast Asia Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.5.6 India Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027
  6.6.2 Brazil Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.6.3 Argentina Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027
  6.7.2 Turkey Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.7.3 Israel Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.7.4 Saudi Arabia Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027
  6.7.5 UAE Homozygous Familial Hypercholesterolemia Epidemiology Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Regeneron Pharmaceuticals
  7.1.1 Regeneron Pharmaceuticals Corporate Summary
  7.1.2 Regeneron Pharmaceuticals Business Overview
  7.1.3 Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.1.4 Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.1.5 Regeneron Pharmaceuticals Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.2.4 Novartis Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.2.5 Novartis Key News
7.3 LIB Therapeutics
  7.3.1 LIB Therapeutics Corporate Summary
  7.3.2 LIB Therapeutics Business Overview
  7.3.3 LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.3.4 LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.3.5 LIB Therapeutics Key News
7.4 NeuroBo Pharmaceuticals
  7.4.1 NeuroBo Pharmaceuticals Corporate Summary
  7.4.2 NeuroBo Pharmaceuticals Business Overview
  7.4.3 NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.4.4 NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.4.5 NeuroBo Pharmaceuticals Key News
7.5 Arrowhead Pharmaceuticals
  7.5.1 Arrowhead Pharmaceuticals Corporate Summary
  7.5.2 Arrowhead Pharmaceuticals Business Overview
  7.5.3 Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.5.4 Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.5.5 Arrowhead Pharmaceuticals Key News
7.6 Amgen
  7.6.1 Amgen Corporate Summary
  7.6.2 Amgen Business Overview
  7.6.3 Amgen Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.6.4 Amgen Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.6.5 Amgen Key News
7.7 Aegerion Pharmaceutical
  7.7.1 Aegerion Pharmaceutical Corporate Summary
  7.7.2 Aegerion Pharmaceutical Business Overview
  7.7.3 Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Major Product Offerings
  7.4.4 Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (2016-2021)
  7.7.5 Aegerion Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Homozygous Familial Hypercholesterolemia Epidemiology Market Opportunities & Trends in Global Market
Table 2. Homozygous Familial Hypercholesterolemia Epidemiology Market Drivers in Global Market
Table 3. Homozygous Familial Hypercholesterolemia Epidemiology Market Restraints in Global Market
Table 4. Key Players of Homozygous Familial Hypercholesterolemia Epidemiology in Global Market
Table 5. Top Homozygous Familial Hypercholesterolemia Epidemiology Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Share by Companies, 2016-2021
Table 8. Global Companies Homozygous Familial Hypercholesterolemia Epidemiology Product Type
Table 9. List of Global Tier 1 Homozygous Familial Hypercholesterolemia Epidemiology Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Homozygous Familial Hypercholesterolemia Epidemiology Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Homozygous Familial Hypercholesterolemia Epidemiology Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2022-2027
Table 30. Regeneron Pharmaceuticals Corporate Summary
Table 31. Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 32. Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 33. Novartis Corporate Summary
Table 34. Novartis Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 35. Novartis Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 36. LIB Therapeutics Corporate Summary
Table 37. LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 38. LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 39. NeuroBo Pharmaceuticals Corporate Summary
Table 40. NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 41. NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 42. Arrowhead Pharmaceuticals Corporate Summary
Table 43. Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 44. Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 45. Amgen Corporate Summary
Table 46. Amgen Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 47. Amgen Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)
Table 48. Aegerion Pharmaceutical Corporate Summary
Table 49. Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Product Offerings
Table 50. Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Homozygous Familial Hypercholesterolemia Epidemiology Segment by Type
Figure 2. Homozygous Familial Hypercholesterolemia Epidemiology Segment by Application
Figure 3. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Homozygous Familial Hypercholesterolemia Epidemiology Revenue in 2020
Figure 8. By Type - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 9. By Application - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 10. By Region - Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 11. By Country - North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 12. US Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 16. Germany Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 17. France Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 24. China Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 28. India Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 30. Brazil Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share, 2016-2027
Figure 33. Turkey Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Homozygous Familial Hypercholesterolemia Epidemiology Revenue, (US$, Mn), 2016-2027
Figure 37. Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Novartis Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Amgen Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)